Bone Marrow Contains Melanoma-reactive CD8\(^+\) Effector T Cells and, Compared with Peripheral Blood, Enriched Numbers of Melanoma-reactive CD8\(^+\) Memory T Cells\(^1\)

Anne Letsch, Ulrich Keilholz, Geraldine Assfalng, Volker Mailänder, Eckhard Thiel, and Carmen Scheibenbogen\(^2\)

University Hospital Benjamin-Franklin, Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, Free University of Berlin, 12200 Berlin, Germany

ABSTRACT

Circulating melanoma-specific T cells can be frequently detected in patients with melanoma. Effective T-cell immunity and tumor surveillance, however, requires the presence of specific T cells in tissues populated by tumor cells. The bone marrow (BM) is a compartment frequently harboring micrometastatic tumor cells. Here, we compared directly ex vivo in peripheral blood (PB) and BM frequencies and differentiation phenotypes of T cells reactive with the melanoma-associated antigen tyrosinase and with autologous melanoma cells. Using intracellular cytokine and tetramer staining, we detected tyrosinase- and melanoma-reactive CD3\(^+\)/CD8\(^+\) T cells in the BM in similar or enhanced frequencies as in PB. Additional characterization of the differentiation subset using CD45RA and CCR7 revealed the presence of specific effector and memory T cells in the BM in all five patients analyzed. Remarkably, the frequency of tyrosinase- and melanoma-specific memory T cells was significantly increased in BM compared with PB. Thus, the BM may be an important compartment for tumor surveillance harboring a tumor-specific memory T-cell pool in addition to effector T cells.

INTRODUCTION

In melanoma there is increasing evidence that T cells can mediate tumor control and melanoma-reactive effector T cells with lytic potential are frequently detected in the PB\(^1\) of melanoma patients (1, 2). The potential of tumor-reactive T cells to migrate to or expand at distinct organ sites is, however, largely unknown. The BM is a compartment of special interest in melanoma and various solid tumors frequently harboring micrometastatic tumor cells (3–9). Several studies show the presence of melanoma cells in the BM either detected immunocytologically or by reverse transcription-PCR for tyrosinase transcripts in 10–30% of melanoma patients (3–9). This is in accordance with the findings in patients with metastatic breast cancer in whom BM micrometastases have most extensively been studied and its negative prognostic impact on survival has been shown (reviewed in Ref. 9). A detection rate of 1–43% of micrometastatic cells in the BM of patients with breast cancer has been reported from various studies (reviewed in Ref. 9).

No direct functional and phenotypical analysis of tumor-specific T-cell responses in BM has been performed thus far. To investigate T-cell immunity in BM, we used IC and tetramer staining to comparatively analyze T cells specific to tumor cells and a tumor antigen in PB and BM. This was possible in five patients with melanoma with a known tyrosinase-specific T-cell response in PB. Additionally, we had in three of these five patients the rare opportunity to simultaneously analyze T cells reactive with autologous melanoma cells from which we had established cell lines (2, 10).

MATERIALS AND METHODS

Patients and Healthy Controls. The characteristics of the four patients with cutaneous melanoma and one patient with ocular melanoma included in this study are shown in Table 1. Patients 1, 3, 4, and 5 had received vaccination with tyrosinase peptides 368–376,370D (HLA-A*0201-binding motif) or 206–214 (HLA-A*2402-binding motif), respectively, as described previously (10). At the time of T-cell analysis, patients 1, 2, and 4 were free of macroscopic disease after resection of melanoma metastases. Patient 3 had complete regression of small cutaneous, lung, and lymph node metastases after repeated vaccination. Patient 5 had stable hepatic and pulmonary metastases of an ocular melanoma after repeated vaccination. The generation of autologous melanoma cell lines in patients 1–3 was performed in our laboratory out of metastases resected from the skin (UKBF-Mel-18, patient 1), the soft tissue of the foot (UKBF-Mel-11, patient 2; Ref. 2), or the small bowel (UKBF-Mel12, patient 3; Refs. 2, 10), respectively. MCs from PB and BM were isolated by density gradient centrifugation using Ficoll-Hypaque and cryopreserved. Before analysis, frozen MC samples were thawed and cultured overnight in medium (Iscoe’s medium supplemented with 10% human serum). This investigation had been approved by the Institutional Ethics Committee and informed consent was obtained.

T-Cell Analysis. IC IFN-γ staining was performed as described previously (2). In brief, MCs (2 × 10\(^6\)) were incubated with 10 μg/ml tyrosinase peptides 368–376, 370D (patients 1, 2, 4, and 5) or 206–214 (patient 3), HIV peptide 476–484 (patients 1, 2, 4, and 5) or without antigen (patient 3) as negative control or autologous tumor cells in a ratio of MC to tumor cells of 10:1. After 2 h, 10 μg brefeldin A (Sigma, Deisenhofen, Germany) were added, and after additional 16 h, MCs were stained extracellularly with fluorescence-conjugated monoclonal antibodies against CD3, CD4, CD8, and, Compared with Peripheral Blood, Enriched Numbers of Melanoma-reactive T Cells 1

1 This work was supported by Deutsche Krebshilfe Grant 10-1072.

2 The abbreviations used are: PB, peripheral blood; BM, bone marrow; CCR, chemokine receptor CC; CCRX, chemokine receptor CXC; IC, intracellular cytokine; MC, mononuclear cell; NED, no evidence of disease; SDF-1, stromal cell-derived factor-1; fluo-3-AM, fluo-3-acetomethylester.
tyrosinase 206

376,370D HLA-A*0201-binding peptide (patients 1, 2, 4, and 5) or spontaneous T-cell response to tyrosinase.

induced by tyrosinase peptide vaccination, whereas patient 2 had a

Table 1. In patients 1, 3, 4, and 5 tyrosinase-specific T cells had been precursor cells and lymphocytes. Patient characteristics are shown in

typical BM particles and a normal distribution of hematological

performed from BM aspirates in all patients showing the presence of

CD34

detected by IC IFN–

0.64% (BM), and 0.31% (PB) and 0.30% (BM), respectively, as

4 with 0.53% (PB)

were rather similar in PB and BM in patients 1

controls.

RESULTS

Detection of Tyrosinase- and Melanoma-reactive T Cells in PB

1). A functional T-cell analysis with IC IFN–

Diagnostics, Mannheim, Germany). Random hexamers and avian myeloblastosis virus reverse transcriptase were used for cDNA synthesis. Tyrosinase, MelanA/MART-1, and porphobilinogen deaminase as housekeeping genes were amplified using published primer sequences and conditions using a LightCycler equipment (Roche Diagnostics). A standard curve was established using artificial plasmids for all three RNA species.

Statistical Analysis. A Wilcoxon signed rank test was calculated to determine whether the frequencies of tyrosinase-specific memory T cells in BM were significantly increased compared with PB. Because of the small sample size, the P value is considered exploratory.

RESULTS

Detection of Tyrosinase- and Melanoma-reactive T Cells in PB

and BM. From five patients with known reactivity to the melanoma-associated antigen tyrosinase in PB simultaneous PB and BM samples were collected. In addition, three of these five patients, an autologous melanoma cell line was available that was specifically recognized by the patients PB T cells. BM samples contained between 2.0 and 5.6% of CD34+ cells in contrast to PB samples in which <0.4% CD34+ cells were present. In addition, cytological smears were performed from BM aspirates in all patients showing the presence of typical BM particles and a normal distribution of hematological precursor cells and lymphocytes. Patient characteristics are shown in Table 1. In patients 1, 3, 4, and 5 tyrosinase-specific T cells had been induced by tyrosinase peptide vaccination, whereas patient 2 had a spontaneous T-cell response to tyrosinase.

We analyzed specific T-cell responses to the tyrosinase 369–376,370D HLA-A*0201-binding peptide (patients 1, 2, 4, and 5) or the tyrosinase 206–214 HLA-A*2402-binding peptide (patient 3) and to the autologous melanoma cells (patients 1–3) in parallel in PB and BM by IC IFN–γ staining after brief exposure to antigen. Unstimulated samples or samples stimulated with an irrelevant HIV peptide is subtracted in the experiments performed with IC IFN–γ staining. The number of IFN–γ-secreting T cells in the absence of antigen or incubated with an irrelevant HIV peptide is subtracted in the experiments performed with IC IFN–γ staining. Specific CD3+CD8+ T cells were separated into distinct subsets based on the expression of CD45RA and CCR7.

![Fig. 1. T-cell responses to tyrosinase peptides in PB and BM of five patients.](image)

![Fig. 2. T-cell responses to the autologous melanoma cells in PB and BM of three patients.](image)

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Union International Contre Cancer stage</th>
<th>Prior systemic treatment</th>
<th>Disease status at time of T-cell analysis in bone marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IIIb</td>
<td>Adjuvant IFN–α, adjuvant tyrosinase peptide vaccination</td>
<td>NED* after resection of skin metastasesa</td>
</tr>
<tr>
<td>2</td>
<td>IV</td>
<td>MAGE-3-protein vaccination, CDPD/DTIC/IFN–α</td>
<td>NED after resection of single site soft tissue/bone metastasis of the forefootb</td>
</tr>
<tr>
<td>3</td>
<td>IV</td>
<td>Adjuvant IFN–α, tyrosinase peptide vaccination</td>
<td>Complete remission of skin, lymph node, and lung metastases after vaccination</td>
</tr>
<tr>
<td>4</td>
<td>IV</td>
<td>Adjuvant interleukin-2 and IFN–α, adjuvant IFN–α, adjuvant tyrosinase peptide vaccination</td>
<td>NED after resection of lymph node metastases</td>
</tr>
<tr>
<td>5</td>
<td>Ocular melanoma IV</td>
<td>Gemcitabine/teosulfan, tyrosinase peptide vaccination</td>
<td>Stable disease of pulmonary and hepatic metastases</td>
</tr>
</tbody>
</table>

* NED, no evidence of disease.

b Metastases from which melanoma cell lines were established.
Among CD45RA/CCR7 subsets are indicated.

CD3 +/H11001 CD8 +/H11001 cells and the CD45RA/CCR7 profile of the C+D subsets of IFN-γ/H9253 and CD8 +/H9253 T cells in BM compared with PB was statistically significant in BM compared with PB. The increase of tyrosinase-specific memory –1, 2, and 5) and of the melanoma-specific memory T cells 1.6

Analyses of the tyrosinase- and melanoma-specific CD3 +/H11001 and CCR7 as described previously (13). Results of the phenotypical T-cell differentiation subsets is based on the expression of CD45RA noma-specific T Cells in PB and BM. The classification of specific antimelanoma response present patient 2 therefore most likely underestimates the magnitude of the frequency of the T-cell response detected against UKBF-Mel-11 in melanoma lesion had expressed high levels of tyrosinase (2). The

differentiation Phenotypes of Tyrosinase-specific and Mela-

oma-specific T Cells in PB and BM. The classification of specific T-cell differentiation subsets is based on the expression of CD45RA and CCR7 as described previously (13). Results of the phenotypical analyses of the tyrosinase- and melanoma-specific CD3 +/CD8 + T-cell differentiation subsets in PB and BM are summarized in Figs. 1 and 2 and illustrated for patient 2 in Fig. 3. Because naive T cells do not usually secrete IFN-γ under the assay conditions used, we considered the specific CD45RA +/CCR7 + T cells detected by IC IFN-γ as early memory T cells (14). In all five patients, tyrosinase-specific T cells and in patients 1–3 also melanoma-specific T cells belonging to memory [CD45RA +/CCR7+, CD45RA-CCR7+ (central memory), CD45RA-CCR7– (effecter memory)] and effecter (CD45RA +/ CCR7+) T-cell subsets were found in PB and BM. Although the quantitative distribution of specific T cells among the four different subsets varied in the five patients, one finding was consistent in all five patients for both targets and for both assays: The proportion of the tyrosinase-specific memory T cells was increased 1.5–4.1-fold (as determined by IC IFN-γ in patients 1–4 and by tetramers in patients 1, 2, and 5) and of the melanoma-specific memory T cells 1.6–10-fold in BM compared with PB. The increase of tyrosinase-specific memory T cells in BM compared with PB was statistically significant (P = 0.04, n = 5, comparing frequencies of all tyrosinase-specific memory T-cell subsets in BM versus PB in the five patients). The enrichment of specific memory T cells in BM was restricted to the early and central memory subset (CD45RA +/CCR7+ and CD45RA-CCR7+) in patients 1, 2, 4, and 5 (Figs. 1 and 2, illustrated for patient 2 in Fig. 3D), whereas the melanoma-specific memory T cells detected in patient 3 were mostly of the effector memory subset (CD45RA-CCR7−, Figs. 1 and 2). Remarkably, this was the only patient in whom we could also observe a strong enrichment of melanoma-reactive effector T cells in BM.

Fig. 3. CD3+/CD8+ T-cell responses to the tyrosinase 368–376, 370/3D peptide detected by IC IFN-γ staining (A and B) or by tetramer staining (C and D) in PB and BM of patient 2. A and B show the CD8/IFN-γ profile of CD3-gated lymphocytes in samples incubated with HIV peptide as negative control (left) or tyrosinase peptide (right). Frequencies of IFN-γ +/CD3+/CD8 + T cells are indicated. C and D show the tetramer staining of CD3-gated T cells and the CD45RA/CCR7 profile of the CD3+/CD8+/tetramer + T cells. Frequencies of CD3+/CD8+/tetramer + T cells and their distribution among CD45RA/CCR7 subsets are indicated.

Fig. 4. T-cell responses to the autologous tumor cell line in PB and BM detected by IC IFN-γ staining and expression and functional analysis of CXCR4 on tumor-specific T cells in patient 3. A and B show the CD8/IFN-γ profile of CD3 gated lymphocytes in samples incubated in the absence of antigen (left) and after exposure to autologous tumor cell line (middle). The right figures show the CXCR4/IFN-γ profile of tumor specific CD3/CD8 gated lymphocytes. C shows the functional CXCR4 analysis that was performed in PB on CD8 + T cells secreting IFN-γ in response to the autologous melanoma cell line detected by IFN-γ secretion assay. Melanoma-reactive CD8 +/IFN-γ+ positive T cells show elevation of intracellular Ca levels indicated by the increase of fluorescence intensity of fluo-3-AM after exposure to the CXCR4 ligand SDF-1 or Ionomycin, which was used as positive control.
To determine whether the T-cell response toward the autologous melanoma cells described above was also present at the time the patients were bearing tumor metastases, additional peripheral blood mononuclear cell samples were analyzed in patients 1–3, which had been drawn 3–35 months earlier, directly before resection of the melanoma lesion from which the melanoma cell lines had been generated. Similar frequencies and phenotypes of melanoma-reactive T cells were found in patients 1–3 in these PB samples with 0.49% (68% CD45RA+CCR7−), 0.34% (27% CD45RA+CCR7−), and 1.3% (92% CD45RA+CCR7−)-specific CD3+CD8+ T cells, respectively, measured by IC IFN-γ (graphic data not shown).

**Melanoma-reactive T Cells Express Functional CXCR4.** The chemokine receptor CXCR4, mediating migration to the ligand SDF-1, which is expressed at high levels in BM, was analyzed on the melanoma-reactive T cells in PB and BM in patients 1–3. Melanoma-reactive T cells were CXCR4high in PB and BM in patients 1 and 2 and CXCR4low with ~25% CXCR4-negative T cells in patient 3 (see Fig. 4, A and B, for patient 3, data from patient 1 and 2 not shown). In patient 3 in whom 1% of the CD3+CD8+ T cells in PB recognized the autologous melanoma cells, we tried to determine the CXCR4 response to the ligand SDF-1 on melanoma-reactive CXCR4low T cells in PB. In these experiments, melanoma-reactive T cells were detected by trapping secreted IFN-γ on the cell surface using a bispecific monoclonal antibody to avoid permeabilization of the cell membrane. CXCR4 expression on the melanoma-reactive IFNγ+ CD8+ T cells was functional as could be shown by elevation of intracellular Ca levels after exposure to SDF-1 (Fig. 4C), suggesting their potential to migrate to the BM.

**Melanoma Cells Express Functional CXCR4 but Are Absent from BM.** Functional CXCR4 expression could be detected on all three melanoma cell lines derived from the patients studied here (data not shown), suggesting that the melanoma cells should be able to migrate to BM. To analyze whether melanoma cells were present in the BM samples, a quantitative real-time PCR for tyrosinase and MelanA/MART-1 was performed, which is known to be one of the most specific and sensitive markers for occult melanoma cells. Tyrosinase and MelanA/MART-1 were expressed in all three patients melanoma tissues from which the cell lines had been generated. No tyrosinase and MelanA/MART-1 expression could be detected in any of the three patients BM samples nor in PB by quantitative real-time PCR.

**DISCUSSION**

In this study, we provide a first direct functional and phenotypical analysis of tumor-reactive T cells in BM. We could show that similar or higher frequencies of melanoma antigen-reactive T cells are present in BM in all 5 patients analyzed. The characterization of the differentiation phenotype of the melanoma-antigen-specific T cells revealed that the BM contained both melanoma-specific effector T cells and memory T cells in all five patients. T cells exhibiting an effector phenotype are those with the highest cytotoxic potential and have been shown to directly mediate tumor cytotoxicity (2, 13). Importantly, specific memory T cells providing long-term immunity were present in all five patients and were constantly found at higher frequencies in BM as in PB. Taken together, these findings suggest that the BM is a compartment where effective tumor surveillance can take place.

The enrichment of specific memory T cells in BM is in accordance with investigations in breast cancer patients in whom tumor-reactive T cells could be expanded from BM but not from PB in the majority of patients (15). In mice, specific T-cell responses against viral epitopes have been found in BM during acute and chronic infection (16–18). Although during the acute infection frequencies of virus-specific T cells were lower in BM than in PB, memory responses were ~2-fold higher in BM as compared with PB (18). The finding of an enrichment of melanoma-specific memory T cells in BM raises the question whether they have been generated in situ upon direct antigenic stimulation or have entered the BM from PB. The detection of melanoma cells in the BM by PCR has been reported in up to one-third of patients with metastatic disease (3–7). Because melanoma cells of all three patients analyzed in this study express functional CXCR4 (which we find in ~50% of melanoma cell lines, unpublished observation), they should have the potential to migrate to the BM. The failure to detect melanoma cells by quantitative PCR in the BM of these three patients does not argue against the possibility that their melanoma cells migrate to the BM because they may become rapidly destroyed by cytolytic T cells present in BM. Thus, we are unable to conclude from our data whether the specific T cells we find in the BM are attracted by specific antigens or whether alternatively the BM is a place where memory T cells preferentially migrate to. The clinical significance of specific T-cell responses in relation to the presence of micrometastatic or metastatic disease could only be clarified by a larger study simultaneously analyzing the presence of tumor-specific T cells and of tumor cells in BM.

The chemokine receptor CXCR4 plays an important role in the migration of cells to the BM, and there is evidence that CXCR4 mediates the metastatic spread of tumor cells to the BM (19). CXCR4 mRNA and surface expression were described in melanoma, and the ligand SDF-1 is expressed at high levels in BM, lung, liver, and lymph nodes, organs that are frequently involved in melanoma metastases (20, 21). Although the majority of PB T cells express CXCR4, it was shown to be functional in response to SDF-1 only in a subpopulation of T cells (22). The demonstration of functional CXCR4 on melanoma-reactive T cells in PB in one patient suggests their potential to migrate to the BM and other compartments with high levels of SDF-1. Recently, it was shown that stimulation of the adhesion molecule L-selectin (CD62L) enhances functional expression of CXCR4 on T cells, resulting in enhanced T-cell migration to SDF-1 (23). Remarkably, L-selectin is expressed on the majority of CCR7−/CD8+ T cells but only on a small subpopulation of the CCR7+ effector memory and effector CD8+ T-cell subsets (13). The differential expression of L-selectin on T cells could result in the preferential migration to and retention of CCR7+ memory T cells in the BM. This hypothesis would fit well to our observation that in four of five patients the enrichment of tyrosinase- and melanoma-specific memory CD8+ T cells in BM is restricted to the CCR7+ subset.

Our finding that the BM contains melanoma-specific effector T cells and enriched numbers of memory T cells has important implications for immunotherapeutic concepts. It provides a rationale for T-cell vaccination strategies in patients with micrometastatic disease in the BM. Furthermore, it suggests that T-cell monitoring in PB may underestimate the type and magnitude of tumor-specific T-cell responses. Finally, the tumor-reactive memory T-cell pool present in BM may be a valuable source for adoptive T-cell therapies.

**REFERENCES**


Bone Marrow Contains Melanoma-reactive CD8+ Effector T Cells and, Compared with Peripheral Blood, Enriched Numbers of Melanoma-reactive CD8+ Memory T Cells

Anne Letsch, Ulrich Keilholz, Geraldine Assfalg, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/17/5582

Cited articles
This article cites 22 articles, 8 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/17/5582.full.html#ref-list-1

Citing articles
This article has been cited by 21 HighWire-hosted articles. Access the articles at:
/content/63/17/5582.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.